MA41431A - Prévention ou traitement de maladie de goutte ou d'acide urique - Google Patents
Prévention ou traitement de maladie de goutte ou d'acide uriqueInfo
- Publication number
- MA41431A MA41431A MA041431A MA41431A MA41431A MA 41431 A MA41431 A MA 41431A MA 041431 A MA041431 A MA 041431A MA 41431 A MA41431 A MA 41431A MA 41431 A MA41431 A MA 41431A
- Authority
- MA
- Morocco
- Prior art keywords
- uric acid
- gout
- prevention
- treatment
- img
- Prior art date
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title abstract 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 229940116269 uric acid Drugs 0.000 title abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 201000001431 Hyperuricemia Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010046337 Urate nephropathy Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne l'utilisation d'un composé de formule (i), d'un sel pharmaceutiquement acceptable de celui-ci, d'un solvate de celui-ci ou d'une composition pharmaceutique le contenant pour réduire le taux d'acide urique, prévenir ou réduire les inflammations et prévenir ou traiter les maladies goutteuses. En particulier, la présente invention concerne l'utilisation d'un composé de formule (i), d'un sel pharmaceutiquement acceptable de celui-ci, d'un solvate de celui-ci ou d'une composition pharmaceutique le contenant dans la fabrication d'un médicament pour le traitement ou la prévention de l'hyperuricémie, goutte, inflammations goutteuses, douleur et néphropathie à l'acide urique. <img file="imga0001.Tif" frnum="0001" he="26" id="ia01" img-content="chem" img-format="tif" inline="no" orientation="portrait" pgnum="0001" wi="43"/> r1 représente un hydrogène, un alkyle en ci-4 ou similaire. R2 représente un alkyle en ci à 10 ou similaire. R3 représente un halogène ou similaire.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510048096 | 2015-01-30 | ||
| CN201510080714 | 2015-02-13 | ||
| CN201510079809 | 2015-02-13 | ||
| CN201510216089 | 2015-04-30 | ||
| PCT/CN2016/000061 WO2016119570A1 (fr) | 2015-01-30 | 2016-01-28 | Prévention ou traitement de maladie de goutte ou d'acide urique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA41431A true MA41431A (fr) | 2017-12-06 |
| MA41431B1 MA41431B1 (fr) | 2021-05-31 |
Family
ID=56542370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA41431A MA41431B1 (fr) | 2015-01-30 | 2016-01-28 | Prévention ou traitement de maladie de goutte ou d'acide urique |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10322132B2 (fr) |
| EP (1) | EP3251675B1 (fr) |
| JP (1) | JP6678685B2 (fr) |
| KR (1) | KR102128810B1 (fr) |
| CN (1) | CN107206002B (fr) |
| AU (1) | AU2016212625B2 (fr) |
| BR (1) | BR112017016065A2 (fr) |
| CA (1) | CA2973746C (fr) |
| CY (1) | CY1124383T1 (fr) |
| DK (1) | DK3251675T3 (fr) |
| EA (1) | EA034139B1 (fr) |
| ES (1) | ES2881872T3 (fr) |
| HR (1) | HRP20211007T1 (fr) |
| HU (1) | HUE054741T2 (fr) |
| IL (1) | IL253726B2 (fr) |
| LT (1) | LT3251675T (fr) |
| MA (1) | MA41431B1 (fr) |
| MX (1) | MX380301B (fr) |
| PL (1) | PL3251675T3 (fr) |
| PT (1) | PT3251675T (fr) |
| SG (2) | SG11201705889VA (fr) |
| SI (1) | SI3251675T1 (fr) |
| SM (1) | SMT202100359T1 (fr) |
| TW (1) | TWI680761B (fr) |
| WO (1) | WO2016119570A1 (fr) |
| ZA (1) | ZA201704600B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018209178A1 (fr) | 2017-05-11 | 2018-11-15 | The Research Foundation For The State University Of New York | Procédé et kit permettant de déterminer la présence de cristaux d'urate monosodique dans un liquide synovial articulaire |
| CN121219290A (zh) | 2023-02-27 | 2025-12-26 | 珊顿医药科技新加坡公司 | 化合物8-氯-3-戊基-3,7-二氢-1h-嘌呤-2,6-二酮的晶型及其制备方法 |
| CN116650490B (zh) * | 2023-06-07 | 2025-05-20 | 中国人民解放军海军军医大学 | 化合物mt-1207在降低尿酸方面的应用 |
| EP4497439A1 (fr) * | 2023-07-28 | 2025-01-29 | Universitat de les Illes Balears | Composés pour le traitement ou la prévention de la goutte |
| TWI902254B (zh) * | 2024-05-16 | 2025-10-21 | 新加坡商珊頓醫藥科技新加坡公司 | 化合物8-氯-3-戊基-3,7-二氫-1h-嘌呤-2,6-二酮的晶型及其製備方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8906792D0 (en) | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
| WO1993016699A1 (fr) * | 1992-02-21 | 1993-09-02 | Smithkline Beecham Corporation | Inhibiteurs du facteur necrotique tumoral |
| AR015966A1 (es) | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito |
| PL1781657T3 (pl) | 2004-02-14 | 2013-08-30 | Glaxosmithkline Ip Dev Ltd | Leki o aktywności wobec receptora HM74A |
| MX2009000169A (es) * | 2006-06-23 | 2009-01-26 | Incyte Corp | Derivados de purinona como agonistas de hm74a. |
| ES2355325T3 (es) * | 2006-06-23 | 2011-03-24 | Incyte Corporation | Derivados de purinona como agonistas de hm74a. |
| WO2010071865A1 (fr) * | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Compositions pharmaceutiques et procédés de traitement de l'hyperuricémie et des troubles associés |
| US20110136835A1 (en) * | 2009-09-14 | 2011-06-09 | Nuon Therapeutics, Inc. | Combination formulations of tranilast and allopurinol and methods related thereto |
| WO2011057110A1 (fr) | 2009-11-06 | 2011-05-12 | Ruprecht-Karls-Universitat-Heidelberg | Agonistes de gpr109a pour le traitement de l'ischémie cérébrale |
-
2016
- 2016-01-28 EP EP16742632.9A patent/EP3251675B1/fr active Active
- 2016-01-28 HR HRP20211007TT patent/HRP20211007T1/hr unknown
- 2016-01-28 SG SG11201705889VA patent/SG11201705889VA/en unknown
- 2016-01-28 AU AU2016212625A patent/AU2016212625B2/en active Active
- 2016-01-28 WO PCT/CN2016/000061 patent/WO2016119570A1/fr not_active Ceased
- 2016-01-28 SI SI201631264T patent/SI3251675T1/sl unknown
- 2016-01-28 SM SM20210359T patent/SMT202100359T1/it unknown
- 2016-01-28 KR KR1020177024392A patent/KR102128810B1/ko active Active
- 2016-01-28 MX MX2017009853A patent/MX380301B/es unknown
- 2016-01-28 ES ES16742632T patent/ES2881872T3/es active Active
- 2016-01-28 PL PL16742632T patent/PL3251675T3/pl unknown
- 2016-01-28 US US15/512,412 patent/US10322132B2/en active Active
- 2016-01-28 DK DK16742632.9T patent/DK3251675T3/da active
- 2016-01-28 BR BR112017016065-0A patent/BR112017016065A2/pt not_active Application Discontinuation
- 2016-01-28 EA EA201791714A patent/EA034139B1/ru unknown
- 2016-01-28 JP JP2017558605A patent/JP6678685B2/ja active Active
- 2016-01-28 LT LTEP16742632.9T patent/LT3251675T/lt unknown
- 2016-01-28 CN CN201680001581.8A patent/CN107206002B/zh active Active
- 2016-01-28 HU HUE16742632A patent/HUE054741T2/hu unknown
- 2016-01-28 MA MA41431A patent/MA41431B1/fr unknown
- 2016-01-28 SG SG10201907026RA patent/SG10201907026RA/en unknown
- 2016-01-28 PT PT167426329T patent/PT3251675T/pt unknown
- 2016-01-28 CA CA2973746A patent/CA2973746C/fr active Active
- 2016-01-29 TW TW105102935A patent/TWI680761B/zh active
-
2017
- 2017-07-07 ZA ZA2017/04600A patent/ZA201704600B/en unknown
- 2017-07-30 IL IL253726A patent/IL253726B2/en unknown
-
2021
- 2021-06-22 CY CY20211100551T patent/CY1124383T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41431A (fr) | Prévention ou traitement de maladie de goutte ou d'acide urique | |
| MA44674A (fr) | Inhibiteurs de bromodomaine | |
| MA47368B1 (fr) | N-[4-fluoro-5-[[(2s,4s)-2-méthyl-4-[(5-méthyl-1,2,4-oxadiazol-3-yl)méthoxy]-1-pipéridyl]méthyl]thiazol-2-yl]acétamide utilisés en tant qu'inhibiteur d'oga | |
| MA45940B1 (fr) | Composé hétérocyclique | |
| MA33450B1 (fr) | Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques | |
| MA38323B1 (fr) | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale | |
| MA49952B1 (fr) | Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations | |
| MA35114B1 (fr) | 1,3-oxazines à titre d'inhibiteurs de bace1 et/ou de bace2 | |
| MA35246B1 (fr) | 1,3-oxazines en tant qu'inhibiteurs de bace1 et/ou de bace2 | |
| MA33239B1 (fr) | 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires | |
| MA54653B1 (fr) | Modulateurs du récepteur de cxcr7 pipéridine | |
| MA37762A1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
| MA33533B1 (fr) | Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles | |
| MA37764A1 (fr) | Composés n-alkyltriazole utilisés comme antagonistes de lpar | |
| MA41633B1 (fr) | Composés amide en tant qu'agonistes du récepteur 5-ht4 | |
| MA40955B1 (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| MA38556A1 (fr) | Inhibiteurs de bace1 | |
| EP2091328A4 (fr) | Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer | |
| MA50013B1 (fr) | Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton | |
| MA39688B1 (fr) | Composés hétéroaryle pour le traitement de maladies ophtalmiques | |
| MA47469B1 (fr) | Dérivés 2-(3-(1h-benzo[d]imidazol-1-yl)propyl)pipéridin-3-ol et composés similaires en tant q'inhibiteurs prs pour le traitement du cancer | |
| MA46268A (fr) | Dérivés de 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma | |
| MA37765A1 (fr) | Composés de pyrazole substitués utilisés comme antagonistes de lpar | |
| MA38694B1 (fr) | Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase | |
| MA33563B1 (fr) | 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl |